

Editorial Board

P. A. Abrahamsson	Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
B. B. Aggarwal	Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
T. Akimoto	Division of Particle Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan
P. Z. Anastasiadis	Department of Cancer Biology, Mayo Cancer Center, Jacksonville, FL, USA
A. Argiris	Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA
J. P. Armand	Institut Claudius Regaud, Toulouse, France
V. I. Avramis	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
D.-T. Bau	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
G. Bauer	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
E. E. Baulieu	INSERM U488 and College de France, Le Kremlin-Bicetre, France
E. J. Benz, Jr.	Dana-Farber Cancer Institute, Boston, MA, USA
J. Bergh	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
F. T. Bosman	Institute of Pathology, University of Lausanne, Switzerland
M. Bouvet	Department of Surgery, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
J. Boyd	Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
G. Broich	Gruppo Policlinico di Monza, Monza, Italy
Ø. S. Bruland	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
J. M. Buatti	Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA
M. M. Burger	Novartis, Basel, Switzerland
M. Carbone	Cancer Research Center of Hawaii, Honolulu, HI, USA
C. Carlberg	Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
J. Carlsson	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
A. F. Chambers	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
P. Chandra	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
L. Cheng	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
J.-G. Chung	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
R. Clarke	Georgetown University Medical Center, Washington, DC, USA
E. De Clercq	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
W. Den Otter	VUMC, Department of Urology, Amsterdam, The Netherlands
E. P. Diamandis	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
G. Th. Diamandopoulos	Department of Pathology, Harvard Medical School, Boston, MA, USA
L. Egevad	Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
D. W. Felsher	Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
J. A. Fernandez-Pol	Metalloproteomics, LLC, Chesterfield, MO, USA
I. J. Fidler	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
A. P. Fields	Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA
H. Fu	Discovery and Developmental Therapeutics Program of Winship Cancer Institute, Emory University, Atlanta, GA, USA
B. Fuchs	Balgrist University Hospital, Zurich, Switzerland
D. Fuchs	Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria

D. Fukumura	Edwin L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA
G. Gabbiani	Department of Pathology, University of Geneva, Switzerland
R. Ganapathi	Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
A. F. Gazdar	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
A. Giordano	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
G. Gitsch	Department of Gynecology and Obstetrics, University of Freiburg, Germany
M. Gnant	Department of Surgery, Medical University of Vienna, Austria
R. H. Goldfarb	R. H. Goldfarb Sopherion Therapeutics, LLC and Translational Oncology and ImmunoEngineering Consulting, Guilford, CT, USA
A. Helland	Oslo University Hospital-Radium Hospital, Oslo, Norway
L. Helson	Sign Path Pharma, Inc., Quakertown, PA, USA
R. Henriksson	Department of Experimental Oncology, Umeå University, Umeå, Sweden
R. M. Hoffman	Department of Surgery, University of California, San Diego, CA, USA
S. C. Jhanwar	Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J. V. Johannessen	Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
R. Jones	Sarcoma Unit, Royal Marsden Hospital, London, UK
B. Kaina	Institute of Toxicology, University of Mainz, Germany
P. -L. Kellokumpu-Lehtinen	Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland
D. G. Kieback	Helios Medical Center Schleswig, Schleswig, Germany
R. Klapdor	Medical Clinic, University of Hamburg, Germany
H. Kobayashi	Laboratory of Molecular Theranostics, NCI/NIH, Bethesda, MD, USA
S. D. Kottaridis	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
G. R. F. Krueger	Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
Pat M. Kumar	Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
Shant Kumar	Department Pathology, University of Manchester Medical School, Manchester, UK
O. D. Laerum	Department of Pathology, The Gade Institute, University of Bergen, Norway
F. J. Lejeune	Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
S. Linder	Department of Medicine and Health, Linköping University, Linköping, Sweden
L. F. Liu	Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
D. M. Lopez	Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
E. Lundgren	Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
Y. Maehara	Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
J. Maher	Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital Campus, London, UK
J. Marescaux	IRCAD, University of Strasbourg, France
J. Mark	Department of Pathology, Kärnshuset, Skövde, Sweden
S. S. Martin	Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA
S. Mitra	The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
S. Miyamoto	Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
S. Moncada	Manchester Cancer Research Centre, University of Manchester, Manchester, UK
M. Mueller	Hochschule Furtwangen University, Villingen-Schwenningen, Germany
F. M. Muggia	New York University Cancer Institute, School of Medicine, NY, USA

M. Namiki	Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan
R. Narayanan	Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
K. Nilsson	Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
S. Pathak	Department of Cell Biology, University of Texas, Houston, TX, USA
J. L. Persson	Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden
G. J. Pilkington	Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
C. D. Platsoucas	College of Sciences, Old Dominion University, Norfolk, VA, USA
A. Polliack	Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
D. Rades	Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
M. Rigaud	Laboratory Biochimie et Génétique Molécules, Faculté de Médecine de Limoges, France
U. Ringborg	Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
M. Roselli	Department of Medical Oncology, University of Rome "Tor Vergata", Italy
S.T. Rosen	Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
A. Schauer	Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
M. Schneider	Department of Organic Chemistry, Bergische University, Wuppertal, Germany
J. Sehouli	Department of Gynecology, Center for Oncological Surgery, Charité Comprehensive Cancer Center, Berlin, Germany
A. Seth	Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
G. V. Sherbet	Cancer Research Unit, University of Newcastle-upon-Tyne, UK
A. Slominski	Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA
G.-I. Soma	Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan
G. S. Stein	Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
T. Stigbrand	Department of Immunology, Umeå University, Umeå, Sweden
T. M. Theophanides	Department of Chemistry, Technical University of Athens, Greece
P. M. Ueland	Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
H. Van Vlierberghe	Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
R.G. Vile	Department of Immunology, Mayo Clinic, Rochester, MN, USA
M. Weller	Department of Neurology, University Hospital Zurich, Zurich, Switzerland
J. Westermarck	Centre for Biotechnology, University of Turku, Turku, Finland
B. Westermarck	Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
Y. Yen	Taipei Medical University, Taipei, Taiwan, ROC
M. R. I. Young	Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA
B. Zumoff	Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA